V8 Peptides — Engineered Performance
Research Library
Glow Stack Explained: GHK-Cu, BPC-157 and TB-500
GLOW StackStacks

Glow Stack Explained: GHK-Cu, BPC-157 and TB-500

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What is in the Glow Stack and how should a researcher read it? Per the product page, one 70 mg co-lyophilized vial holds 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500 at ≥98% HPLC purity, stored at 2–8 °C or −20 °C long-term. The 5:1:1 ratio is by mass; in molecules GHK-Cu outnumbers BPC-157 by roughly 18 to 1. A blend answers whether the mixture changes a readout, not which component caused it. Compute concentrations with the calculator. For laboratory research use only.

The Glow Stack is easy to describe and easy to misread. Three peptides, one vial, a blue cake. The questions a researcher actually has are more specific: how much of each component is in the vial, why the proportions are what they are, which published papers belong to which component, and what a single co-lyophilized blend can and cannot tell you about any one of them. This guide reads the vial component by component and then as a system.

The vial, as the product page describes it

The Glow Stack product page lists a single size of 70 mg total peptide, split as 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500, supplied as a co-lyophilized powder in a sealed clear glass research vial with purity listed at ≥98% by HPLC. Sequence and identity details are reported on the certificate of analysis where one is published. Storage is stated as refrigerate at 2–8 °C, or −20 °C for long-term holding, protected from heat, moisture and light. The page also notes that the copper complex colors the cake and the solution blue, which is expected for this material.

ComponentMass per vialShare of peptide massChemical character
GHK-Cu50 mg71.4%Copper(II) complex of the tripeptide Gly-His-Lys
BPC-15710 mg14.3%Synthetic 15-residue peptide, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
TB-50010 mg14.3%Peptide derived from thymosin beta-4
Total70 mg100%Fixed 5:1:1 mass ratio

The pillar article GLOW blend overview covers reconstitution and the rationale in a single document. This page takes a different cut: it handles the 5:1:1 ratio as a design fact that deserves its own explanation.

Mass ratio is not molar ratio

A label that says 5:1:1 describes milligrams. Receptors, enzymes and binding sites respond to molecules, so any experiment that asks "how many molecules of each reach the cells" has to convert. The conversion uses molar mass: moles equal milligrams divided by molar mass in g/mol, divided by one thousand to reach millimoles. Two of the three components have molar masses that can be taken from the literature: BPC-157 has a molar mass of about 1419 g/mol (computed from its sequence), and GHK-Cu comes to about 404 when the 340 g/mol tripeptide is combined with one copper atom.

QuantityGHK-CuBPC-157
Mass in vial50 mg10 mg
Approximate molar mass404 g/mol1419 g/mol
Amount of substanceabout 0.124 mmolabout 0.0070 mmol
Molar ratio (GHK-Cu : BPC-157)about 17.6 : 1

So a "5:1" mass ratio between GHK-Cu and BPC-157 is closer to "18:1" in molecules. The third component, TB-500, is not included in the arithmetic because the exact molar mass depends on which thymosin beta-4-derived sequence the certificate reports; read that figure from the lot document on the COA page and apply the same formula. These are net-peptide figures; real material also carries counterions and moisture, which is why a vial label is a starting point and not a measured peptide content.

GHK-Cu: the copper complex that fixes the ratio

GHK-Cu is the largest share of the vial by mass and by number. The tripeptide was characterized in the 1970s and 1980s as a plasma factor that forms a complex with copper(II); in a 1980 report, Pickart and colleagues showed that it readily formed copper complexes and enhanced uptake of the metal into cultured hepatoma cells, and suggested a role as a copper transport factor (Pickart et al., 1980). Later reviews of the cell and tissue literature describe effects on collagen and glycosaminoglycan synthesis in dermal fibroblast models and on gene expression (Pickart and Margolina, 2018; Pickart et al., 2015). Those are descriptions of what has been studied in cells and animals; they are not endorsements of any use.

For a lab, the important chemical point is that copper binding makes GHK-Cu a coordination compound. Copper(II) can participate in redox chemistry, which is why a blend that contains it deserves a stability question that single peptides do not raise. The library addresses that directly in does copper degrade other peptides in a blend, and the single-compound pillar is GHK-Cu research overview. The standalone material is on the GHK-Cu product page.

BPC-157: what the cited papers actually examined

BPC-157 is a 15-residue peptide whose published literature is dominated by rodent injury models. A 2003 study in the Journal of Orthopaedic Research examined a transected rat Achilles tendon model and also reported effects on tendon cell growth in vitro (Staresinic et al., 2003). A 2014 study isolated tendon fibroblasts from rat Achilles tendon and reported, from cDNA microarray analysis, that growth hormone receptor expression was altered by BPC-157 in those cells (Chang et al., 2014). Both papers are single-model, preclinical studies and the same caution applies as for any early literature: effect sizes in one laboratory model do not establish a general mechanism. The single-compound background is in BPC-157 research overview, and the vial is described on the BPC-157 product page.

TB-500: the actin-regulation component

TB-500 is described on the V8 page as derived from thymosin beta-4 and used as a tool in actin-regulation and cell-migration assays. Thymosin beta-4 is a small actin-sequestering protein; reviews of the field have discussed how this intracellular function sits alongside reported effects on tissue repair (Goldstein et al., 2005), and an early paper reported effects on angiogenesis, wound healing and hair follicle development (Philp et al., 2004). A cell-migration scratch assay or a transwell assay is the usual way to turn that background into a measurable question. The comparison with the full-length protein is explained in TB-500 vs thymosin beta-4.

Why one vial: the design logic and its limits

A co-lyophilized blend gives three practical things. The components arrive already in a fixed proportion, which removes pipetting variance between them; one reconstitution step replaces three; and the same solution goes to every well, so differences between conditions are not caused by different prep days. Those are real conveniences when the question is "what does the combination do in this cell model".

The same fixed proportion is a limitation when the question is "which component did it". A blend cannot separate additive effects from synergy, because there is no way to change one component without changing the others. The design that does answer that question uses single-compound controls: the combination, each component alone at the concentration it has in the combination, and each pair if the budget allows. The structure of that experiment is laid out in Glow Stack vs individual peptides; broader context on blends is in peptide blends and research stacks.

Experimental questionBlend vial sufficient?What else is needed
Does the three-peptide mixture change a readout in this cell model?YesVehicle control and a copper-matched control
Which component drives the change?NoSingle-compound vials at matched concentrations
Is the effect additive or synergistic?NoFull dose-matrix design and a formal synergy model
Does the blue color or copper content matter?NoA copper-free blend or free copper(II) at matched molarity

Handling in brief

Because the three components are at different mass amounts, each ends up at its own concentration after reconstitution, and the arithmetic is the same for each: concentration in mg/mL equals component mass in mg divided by diluent volume in mL. The GHK-Cu concentration will always be five times that of each other peptide by mass, whatever the volume. Use the reconstitution calculator to compute figures for the volume chosen and write them into the lab record. The bench steps, storage tiers and freeze-thaw cautions are in Glow peptide reconstitution and storage, and the neighbouring blends are compared in GLOW vs KLOW vs Wolverine. A hue change away from the expected blue, or visible particulate, is a reason to stop and document, not to proceed.

Reading the label before you design around it

Four lines of the product page do most of the work in a methods section: the 50/10/10 split, the 70 mg total, the ≥98% HPLC purity figure and the storage line. Remember that the purity figure is a chromatographic statement for the blend and that a copper complex often elutes and ionizes differently from the free peptides, so the certificate is the place to check how each component was confirmed. The catalog sits at the research shop, and sourcing considerations are in where to buy the Glow Stack.

Frequently asked questions

What is in the Glow Stack vial?

According to the product page, 70 mg of co-lyophilized peptide: 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500, with purity listed at ≥98% by HPLC.

What does the 5:1:1 ratio mean?

It is a mass ratio: five parts GHK-Cu to one part BPC-157 to one part TB-500 by milligrams. The molar ratio is different because the molecules have different sizes.

Why is the Glow Stack blue?

GHK-Cu is a copper(II) complex, and the copper gives the cake and the reconstituted solution a blue color. The product page notes this is normal for the material.

How do I convert the mass ratio to a molar ratio?

Divide each component's mass in milligrams by its molar mass in g/mol and compare the results. For GHK-Cu (about 404) and BPC-157 (about 1419), a 5:1 mass ratio works out to roughly 18:1 in molecules.

Can a blend show which peptide caused an effect?

No. A fixed-ratio blend cannot separate component contributions. Single-compound controls at matched concentrations are required for that question.

What papers support the BPC-157 component?

The cited examples are a rat Achilles tendon study (Staresinic 2003) and a tendon-fibroblast gene-expression study (Chang 2014). Both are preclinical and from specific model systems.

What is TB-500 in this blend?

The product page describes it as derived from thymosin beta-4 and used as a tool in actin-regulation and cell-migration assays. The certificate of analysis gives the identity details.

How should the Glow Stack be stored?

The product page states refrigerate at 2–8 °C, −20 °C for long-term, and protect from heat, moisture and light.

Is there a concentration table for this vial?

This page gives the formula only, concentration equals mass divided by volume for each component. The reconstitution calculator computes the figures for any volume.

Does the copper affect the other peptides?

It is a legitimate stability question for any blend containing a copper complex. The library article on copper in blends discusses it, and lot documents are on the COA page.

Research-use statement

Everything on this page is educational background for laboratory research use only. V8 Peptides products are sold as research materials, not for human or animal consumption, and nothing here describes a use outside the laboratory. Browse the research catalog, check lot documents on the COA page, or run volumes through the reconstitution calculator.

Related reading: GHK-Cu, BPC-157 and TB-500 Combinations: Evidence.

References

  1. Pickart L, Freedman JH, Loker WJ, et al. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288(5792):715-717. doi:10.1038/288715a0
  2. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987
  3. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108
  4. Staresinic M, Petrovic I, Novinscak T, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. doi:10.1016/S0736-0266(03)00110-4
  5. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. doi:10.3390/molecules191119066
  6. Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. doi:10.1016/j.molmed.2005.07.004
  7. Philp D, Badamchian M, Scheremeta B, et al. Thymosin β4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. doi:10.1016/j.mad.2003.11.005

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.